Previous 10 | Next 10 |
NeoGenomics ( NASDAQ: NEO ) is trading 13.5% higher after the company reported better-than-expected Q2 result, helped by clinical service unit. The company, who's new CEO Chris Smith is all set to take his position on August 15, posted total revenue of $12...
NeoGenomics press release ( NASDAQ: NEO ): Q2 Non-GAAP EPS of -$0.16 beats by $0.07 . Revenue of $125.07M (+2.8% Y/Y) beats by $1.81M . "During a challenging time in our business, our people have rallied together as we welcome talented new leaders, embark on ...
Second-Quarter 2022 Results and Highlights Consolidated revenue increased 3% to $125 million Clinical Services revenue increased 4% to $106 million Pharma Services revenue decreased 4% to $19 million Chris Smith appointed CEO effective August 15, 2022 FORT MYERS, ...
NeoGenomics ( NASDAQ: NEO ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.23 and the consensus Revenue Estimate is $123.26M (+1.3% Y/Y). Over the last 2 years, NEO has beaten EPS estimates ...
NeoGenomics ( NASDAQ: NEO ) has been appointed Chris Smith as CEO and a member of the board of directors, effective Aug. 15, 2022. Smith will replace chair of the board and Interim CEO Lynn Tetrault, who will resume her role as independent chair of the board. Prior to this...
Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board FT. MYERS, FL / ACCESSWIRE / July 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today an...
FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its second quarter 2022, financial results on Tuesday, August 9, 2022. The Compan...
We may have seen the bottom already. The S&P 500 is up 6.4% in 2 weeks. The NASDAQ is up 9.2%. The market is trying to tell us something. A long climb down the mountain Here is a year-to-date chart of the S&P 500 index. Was the June 16 th low of 3...
NeoGenomics fails to warrant an inclusion into a long-only, equity focused portfolio amid the current climate. There are better alternatives to align with the equity risk premia set to drive equity returns in the coming years. We've priced NEO at ~$9.70, implying little to no upsi...
On June 9, Enzo Biochem announced a new strategic review that may finally lead to the sale of the long-mismanaged company. Since late 2021, positive changes have taken place - long-time CEO Rabbani was replaced with an independent CEO, an experienced activist was appointed to the Boar...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...